470 related articles for article (PubMed ID: 32867025)
1. Resisting Resistance to Immune Checkpoint Therapy: A Systematic Review.
Haibe Y; El Husseini Z; El Sayed R; Shamseddine A
Int J Mol Sci; 2020 Aug; 21(17):. PubMed ID: 32867025
[TBL] [Abstract][Full Text] [Related]
2. Treg-mediated acquired resistance to immune checkpoint inhibitors.
Saleh R; Elkord E
Cancer Lett; 2019 Aug; 457():168-179. PubMed ID: 31078738
[TBL] [Abstract][Full Text] [Related]
3. Can Immunogenic Chemotherapies Relieve Cancer Cell Resistance to Immune Checkpoint Inhibitors?
Rivera Vargas T; Apetoh L
Front Immunol; 2019; 10():1181. PubMed ID: 31191545
[TBL] [Abstract][Full Text] [Related]
4. Immune checkpoint blockade therapy for cancer: An overview of FDA-approved immune checkpoint inhibitors.
Hargadon KM; Johnson CE; Williams CJ
Int Immunopharmacol; 2018 Sep; 62():29-39. PubMed ID: 29990692
[TBL] [Abstract][Full Text] [Related]
5. Immune checkpoint inhibitors.
Hui E
J Cell Biol; 2019 Mar; 218(3):740-741. PubMed ID: 30760493
[TBL] [Abstract][Full Text] [Related]
6. New Clinical Approaches and Emerging Evidence on Immune-Checkpoint Inhibitors as Anti-Cancer Therapeutics: CTLA-4 and PD-1 Pathways and Beyond.
Christodoulou MI; Zaravinos A
Crit Rev Immunol; 2019; 39(5):379-408. PubMed ID: 32422018
[TBL] [Abstract][Full Text] [Related]
7. Vasculitis associated with immune checkpoint inhibitors-a systematic review.
Daxini A; Cronin K; Sreih AG
Clin Rheumatol; 2018 Sep; 37(9):2579-2584. PubMed ID: 29923081
[TBL] [Abstract][Full Text] [Related]
8. Dissecting the mechanisms of immune checkpoint therapy.
Sharma P; Allison JP
Nat Rev Immunol; 2020 Feb; 20(2):75-76. PubMed ID: 31925406
[No Abstract] [Full Text] [Related]
9. Interventional therapy combined with immune checkpoint inhibitors: Emerging opportunities for cancer treatment in the era of immunotherapy.
Chang X; Lu X; Guo J; Teng GJ
Cancer Treat Rev; 2019 Mar; 74():49-60. PubMed ID: 30831375
[TBL] [Abstract][Full Text] [Related]
10. Genomic correlates of response to immune checkpoint blockade.
Keenan TE; Burke KP; Van Allen EM
Nat Med; 2019 Mar; 25(3):389-402. PubMed ID: 30842677
[TBL] [Abstract][Full Text] [Related]
11. Translational Biomarkers and Rationale Strategies to Overcome Resistance to Immune Checkpoint Inhibitors in Solid Tumors.
Chen JA; Ma W; Yuan J; Li T
Cancer Treat Res; 2020; 180():251-279. PubMed ID: 32215873
[TBL] [Abstract][Full Text] [Related]
12. [Predictive biomarkers of efficacy of checkpoint blockade inhibitors in cancer treatment].
Duruisseaux M; Lize-Dufranc C; Badoual C; Bibeau F
Ann Pathol; 2017 Feb; 37(1):46-54. PubMed ID: 28131419
[TBL] [Abstract][Full Text] [Related]
13. Predictive Biomarkers for Checkpoint Immunotherapy: Current Status and Challenges for Clinical Application.
Tray N; Weber JS; Adams S
Cancer Immunol Res; 2018 Oct; 6(10):1122-1128. PubMed ID: 30279188
[TBL] [Abstract][Full Text] [Related]
14. Study and analysis of antitumor resistance mechanism of PD1/PD-L1 immune checkpoint blocker.
Wang Z; Wu X
Cancer Med; 2020 Nov; 9(21):8086-8121. PubMed ID: 32875727
[TBL] [Abstract][Full Text] [Related]
15. Recent advances in the clinical development of immune checkpoint blockade therapy.
Ghahremanloo A; Soltani A; Modaresi SMS; Hashemy SI
Cell Oncol (Dordr); 2019 Oct; 42(5):609-626. PubMed ID: 31201647
[TBL] [Abstract][Full Text] [Related]
16. Progress of immune checkpoint therapy in the clinic (Review).
Fan Y; Zhang C; Jin S; Gao Z; Cao J; Wang A; Li D; Wang Q; Sun X; Bai D
Oncol Rep; 2019 Jan; 41(1):3-14. PubMed ID: 30365127
[TBL] [Abstract][Full Text] [Related]
17. Checkpoint inhibitors in AML: are we there yet?
Ghosh A; Barba P; Perales MA
Br J Haematol; 2020 Jan; 188(1):159-167. PubMed ID: 31808941
[TBL] [Abstract][Full Text] [Related]
18. Understanding and overcoming the resistance of cancer to PD-1/PD-L1 blockade.
Shergold AL; Millar R; Nibbs RJB
Pharmacol Res; 2019 Jul; 145():104258. PubMed ID: 31063806
[TBL] [Abstract][Full Text] [Related]
19. Targeting Multiple Receptors to Increase Checkpoint Blockade Efficacy.
Zahavi DJ; Weiner LM
Int J Mol Sci; 2019 Jan; 20(1):. PubMed ID: 30621125
[TBL] [Abstract][Full Text] [Related]
20. Resistance mechanisms to checkpoint inhibitors.
Weiss SA; Sznol M
Curr Opin Immunol; 2021 Apr; 69():47-55. PubMed ID: 33676271
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]